Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
BioTrackTHC to Present and Exhibit in San Jose

2018-07-19 globenewswire
GREENWOOD VILLAGE, CO, July 19, 2018 (GLOBE NEWSWIRE) -- BioTrackTHC, a Helix TCS, Inc. (OTCQB: HLIX) company, will be attending the National Cannabis Industry Association’s (NCIA) Cannabis Business Summit and Expo in San Jose, California next week. The company will have team members participating in two lounge discussion sessions focused on cultivation tracking and dispensary point of sale best practices for the future of cannabis business operations.
JGLDD HLIX

5
HLIX / Helix TCS, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-22 fintel.io
Helix TCS, Inc. (OTC:HLIX) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Helix TCS, Inc. (OTC:HLIX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
SGEN JGLDD HLIX

1
HLIX / Helix TCS, Inc. CURRENT REPORT (Current Report)

2018-06-05 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
HLIX

1
Helix TCS Inc. and BioTrackTHC Close Previously Announced Merger

2018-06-04 globenewswire
GREENWOOD VILLAGE, CO , June 04, 2018 (GLOBE NEWSWIRE) -- Helix TCS, Inc. (OTCQB: HLIX), in conjunction with its strategic capital partner, Rose Capital, is pleased to announce the closing of its previously reported merger with Bio-Tech Medical Software, Inc. dba BioTrackTHC. The merger closed on June 1st. Zachary L. Venegas will continue as the CEO of Helix TCS, Inc., and is to assume the role of Executive Chairman for the combined company.
JGLDD HLIX

1
Helix TCS, Inc. Announces 63% Revenue Growth in Q1 2018

2018-05-16 globenewswire
GREENWOOD VILLAGE, CO. , May 16, 2018 (GLOBE NEWSWIRE) -- Helix TCS, Inc. (OTCQB: HLIX), the leading provider of integrated operating environment solutions for the legal cannabis industry, announced its first quarter 2018 financial results today.
JGLDD HLIX

1
Helix TCS Inc. to Present at the Planet MicroCap Showcase 2018 on April 25

2018-04-10 accesswire
GREENWOOD VILLAGE, CO / ACCESSWIRE / April 10, 2018 / HELIX TCS INC (OTCQB: HLIX), a premier provider of integrated operating environment solutions for the legal cannabis industry, will present at the Planet MicroCap Showcase at 10:00 am (PST) on Wednesday, April 25, 2018 and will conduct 1on1 meetings on April 26, 2018.
JGLDD HLIX

1
HLIX / Helix TCS, Inc. AMENDMENT NO.1 TO ANNUAL REPORT (Annual Report)

2018-04-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20
HLIX

1
BRIEF-Helix TCS, Inc. Announces Record Revenues For 2017

2018-04-02 reuters
* HELIX TCS, INC. ANNOUNCES RECORD REVENUES FOR 2017 Source text for Eikon: Further company coverage:
JGLDD HLIX

1
Helix TCS, Inc. Announces Record Revenues for 2017

2018-04-02 globenewswire
GREENWOOD VILLAGE, CO , April 02, 2018 (GLOBE NEWSWIRE) -- Helix TCS, Inc. (OTCQB: HLIX), the leading provider of integrated operating environment solutions for the legal cannabis industry, announced its 2017 financial results today.
JGLDD HLIX

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

2h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...